Earnings ·
Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2026, revealing a net…
MISTMilestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2026, revealing a net loss of $28.6 million, or $0.21 per share, compared to a $13.0 million loss in the prior year period. Product revenues reached $0.6 million, driven by the commercial launch of CARDAMYST (etripamil) nasal spray for PSVT, which saw over 1,500 scripts filled and coverage expand to approximately 50% of commercially insured lives in the U.S. The company holds $170.6 million in cash and short-term investments, providing a runway into the second half of 2027. Additionally, Milestone announced that its Phase 3 ReVeRA-301 trial for AFib-RVR has activated clinical sites and begun patient enrollment. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines.